BiotechTube
CARTemis Therapeutics

CARTemis Therapeutics

Munich, Germany· Est.
cartemis.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CARTemis Therapeutics is a private, pre-clinical stage biotech developing next-generation CAR-T cell therapies for oncology. Founded in 2019 in Munich, the company has secured non-dilutive grant funding, including €4.6 million in 2023, and is actively building partnerships, as evidenced by its recent collaboration with TQ Therapeutics. Led by CEO Anthea Wirges, a recognized innovator, CARTemis is positioning itself in the competitive cell therapy space with a focus on advanced engineering to overcome current limitations of CAR-T treatments.

Oncology

Technology Platform

Advanced engineering approaches for CAR-T cell therapy, likely focused on improving persistence, safety, and efficacy, particularly in solid tumors.

Opportunities

The large and growing CAR-T market, especially the massive unmet need in solid tumors, presents a multi-billion dollar opportunity.
Advanced engineering that improves safety or efficacy could capture significant market share.
Strong EU/German grant funding environment supports early development.

Risk Factors

High scientific risk of translating novel engineering into safe/effective human therapies.
Intense competition from large pharma and well-funded biotechs.
Financial risk associated with dependence on future fundraising to reach clinical milestones.

Competitive Landscape

Highly competitive with established players (Novartis, Gilead, BMS/Juno) and numerous biotechs developing next-gen CAR-T platforms. Differentiation requires demonstrating clear superiority in clinical trials. CARTemis is a small, early-stage entrant in this crowded field.

More companies in Cell & Gene Therapy →More companies in Germany →